Haemophilus influenzae type b polysaccharide capsule — Drug Target

All drugs that target Haemophilus influenzae type b polysaccharide capsule — marketed and clinical-stage. Includes 2 drug classes acting on this target.

Drug classes

Conjugate vaccine · vaccine

Marketed (1)

• Hib conjugate vaccine · Public Health England · Conjugate vaccine · Immunology
  The Hib conjugate vaccine stimulates the immune system to produce antibodies against Haemophilus influenzae type b by conjugating the bacterial polysaccharide capsule to a protein carrier.

Phase 3 pipeline (4)

• Hib Vaccine Group · Beijing Minhai Biotechnology Co., Ltd · vaccine · Immunology
  Hib vaccine stimulates the immune system to produce antibodies against Haemophilus influenzae type b (Hib) bacteria, preventing infection.
• Hib conjugate vaccine (ActHIB) · GlaxoSmithKline · Conjugate vaccine · Immunology / Infectious Disease
  ActHIB is a conjugate vaccine that stimulates the immune system to produce antibodies against Haemophilus influenzae type b (Hib) by linking the bacterial polysaccharide capsule to a protein carrier.
• Minhai-HIB · Beijing Minhai Biotechnology Co., Ltd · Conjugate vaccine · Immunology / Infectious Disease
  Minhai-HIB is a Haemophilus influenzae type b (Hib) conjugate vaccine that stimulates immune responses against the polysaccharide capsule of H. influenzae type b bacteria.
• CombAct-HIB® · Sanofi Pasteur, a Sanofi Company · Conjugate vaccine · Immunology / Infectious Disease
  CombAct-HIB is a combination vaccine that provides immunization against Haemophilus influenzae type b (Hib) by stimulating antibody production against the bacterial polysaccharide capsule.